Pharma generics: Semaglutide patent expiry to open Rs 50-billion opportunity; Indian players eye FY27 boost
The impending patent expiry of semaglutide drugs across India, emerging markets and select regulated markets such as Canada and Brazil is expected to create a revenue opportunity of more than Rs 50 billion for generic pharmaceutical companies over the next 12 to 15 months, according to an industry update by Systematix Institutional Research.The report said…
